All News
ICYMI: Proinflammatory Diet Increases Gout Risk
d
MedPage Today
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated. Data from the two iterations of the Nurses' Health Study, in which more than 170,000 women were followed for more than two decades, indicated that diets scoring high on the Empirical Dietary Inflammatory Pattern (EDIP) index nearly doubled the risk for new-onset gout after adjusting for body mass index.
Read Article
ICYMI: Axial Involvement in Psoriatic Arthritis
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
Read Article
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read Article
ARD's Impact Factor
The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc
Dr. John Cush RheumNow ( View Tweet)
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N
Dr. John Cush RheumNow ( View Tweet)
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population.
https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO
Dr. John Cush RheumNow ( View Tweet)
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Dr. John Cush RheumNow ( View Tweet)
Upcoming Lupus Nephritis Pipeline
1. Gazyva (obinutuzumab) – due for FDA/EMA decision
2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN
3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/jEv2uvhkqK
Dr. John Cush RheumNow ( View Tweet)
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/zrskHdw9Jx https://t.co/jkqygmfJPv
Dr. John Cush RheumNow ( View Tweet)
MRI Lesions in Early axSpA vs Non-axSpA
Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/sVWpyUT1IY https://t.co/wzobROoH1K
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors: The Latest from the JAK-pot Study
Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory https://t.co/KiOZuphQTx
Dr. John Cush RheumNow ( View Tweet)
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
Dr. John Cush RheumNow ( View Tweet)
AI Advances axSpA Diagnosis with Multimodal MRI
Dr. Bella Mehta reports on abstract OP0307 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/fpgwQniSA5 https://t.co/EbT9v821xb
Dr. John Cush RheumNow ( View Tweet)
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Dr. Nelly Ziade discusses abstract OP0175 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/cyDUCGU6Pc https://t.co/jdsTEB3Rqw
Links:
Dr. John Cush RheumNow ( View Tweet)
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/rbK3Y1NHVI https://t.co/eYPdbx87kt
Links:
Dr. John Cush RheumNow ( View Tweet)
Assessment of Peripheral Arthritis in Spondyloarthritis
Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/E6l6qvNnox https://t.co/gLbMjF406q
Dr. John Cush RheumNow ( View Tweet)
Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life
Dr. Jiha Lee reports on abstract POS0402 - THE ROLE OF AGEING IN THE RELATIONSHIP BETWEEN CHRONIC MUSCULOSKELETAL PAIN AND HEALTH-RELATED QUALITY OF LIFE: THE MAASTRICHT STUDY - presented at the 2025 EULAR https://t.co/AiP57hXIRB
Dr. John Cush RheumNow ( View Tweet)
Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation
Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal https://t.co/Sa10k6neRP
Dr. John Cush RheumNow ( View Tweet)
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” framework has https://t.co/NYgivNRgUV
Dr. John Cush RheumNow ( View Tweet)